Conference Coverage
Conference Coverage
Consortium study falls short of expectations
The North American PTCL Consortium set out to find a treatment that could best CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and...
Conference Coverage
Longer-term safety of radium-223 is reassuring
Major finding: At 1.5 years post treatment, there was a 3% incidence of myelosuppression and a single case of aplastic anemia in the radium-223...
Conference Coverage
Older men with prostate cancer have greater risk of CVD, diabetes after prolonged hormonal therapy
Major Finding: The risks of cardiovascular disease and diabetes were elevated after more than 2 years of ADT among men in their mid-70s.Data...
Conference Coverage
Regimen shows promise for ENKTL
The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort of 60 Chinese patients. P...
Conference Coverage
New insights into aromatase inhibitor therapy nonpersistence
Major finding: Breast cancer patients with at least three of five self-reported symptoms prior to going on adjuvant aromatase inhibitor therapy...
Conference Coverage
TNFRII may play key role in CTCL, speaker says
The team discovered that a mutation in this receptor—TNFRII T377I—is present in patients with mycosis fungoides (MF) and those with Sézary...
Conference Coverage
Metastatic RCC patients taking common antihypertensives lived longer
Major Finding: Overall survival was 27 months among users of angiotensin system inhibitors and 17 months among nonusers (hazard ratio, 1.21; P = ....
Conference Coverage
Radiation therapy has long-term benefit in prostate cancer
Major finding: Addition of radiation therapy to lifelong antiandrogen therapy reduced 10-year prostate cancer–specific mortality from 19% to 8%....
Conference Coverage
Inhibitor appears active in relapsed/refractory TCLs
Among 26 evaluable patients, 9 experienced partial responses to treatment with IPI-145, and 1 achieved a complete response, for an overall...
Conference Coverage
Enzalutamide improves survival in chemo-naive metastatic prostate cancer
Major finding: Compared with placebo, enzalutamide yielded better overall survival (hazard ratio, 0.71) and radiographic progression-free survival...
Conference Coverage
A new prognostic model for PTCL?
Researchers analyzed nearly 9000 patients diagnosed with PTCL in the US and found evidence to suggest that patient age and race, as well as...